Therapeutic targets in radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 2, 2001, Pages 319-326

  Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C 225; Cisplatin; Epidermal growth factor receptors; Farnesyltransferase inhibitors; Ras; Tirapazamine; Tumor hypoxia

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GGTI 298; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIRAPAZAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY;

ALKYL AND ARYL TRANSFERASES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL HYPOXIA; DOSE FRACTIONATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, RAS; HEAD AND NECK NEOPLASMS; HUMANS; METHIONINE; NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0035254642     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01482-6     Document Type: Conference Paper

References (50)

1. The role of the H-ras oncogene in radiation resistance and metastasis
2. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation
3. Studies on the influence of the presence of an activated ras oncogene on the in vitro radiosensitivity of human mammary epithelial cells
4. Ras oncogenes in human cancer; A review
5. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
6. Benzodiazepine peptidomimetics; Potent inhibitors of Ras farnesylation in animal cells
7. Farnesyltransferase inhibition causes morphologic reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
8. Non-Ras targets of farnesyltransferase inhibitors; Focus on Rho
9. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts
10. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes
11. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
12. Farnesyltransferase inhibitors potentiate the anti-tumor effect of radiation on a human tumor xenograft expressing activated H-ras
13. Signal transduction by receptors with tyrosine kinase activity
14. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma
15. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
16. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
17. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
18. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
19. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro
20. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx; tumor dose-response and repopulation
21. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death
22. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity
23. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
24. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma
25. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
26. Epidermal growth factor receptor inhibition in cancer therapy; biology, rationale and preliminary clinical results
27. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells
28. Phase I study of anti-epidermal growth factor receptor (EGFR) antibody C225 in combination with irradiation on patients with advanced squamous cell carcinoma of the head and neck (SCCHN)
29. Oxygenation of human tumors; evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements
30. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
31. Measurement of human tumor oxygenation status by a polarographic needle electrode
32. Cells at intermediate oxygen levels can be more important than the 'hypoxic fraction' in determining tumor response to fractionated radiotherapy
33. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
34. Oxygenation of head and neck cancer; changes during radiotherapy and impact on treatment outcome
35. Oxygenation predicts radiation response and survival in patients with cervix cancer
36. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix
37. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
38. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
39. Tumor hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix
40. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
41. Hypoxia-specific cytotoxins in cancer therapy
42. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation
43. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical
44. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors
45. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin
46. Extraordinary tumor control in Phase I trial of concurrent tirapazamine cisplatin and radiotherapy for far advanced head and neck cancer
47. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents; A new class of bioreductive agent
48. AQ4N; An alkylaminoanthraquinone N-oxides showing bioreductive potential and positive interaction with radiation in vivo
49. Tirapazamine plus cisplatin vs. cisplatin in advanced nonsmall-cell lung cancer; A report of the international CATAPULT I study group
50. Modulation of radiation response following epidermal growth factor receptor blockade in squamous cell carcinomas; Inhibition of damage repair, cell cycle kinetics and tumor angiogenesis